OTCMKTS:ROSGQ Rosetta Genomics (ROSGQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Rosetta Genomics Stock (OTCMKTS:ROSGQ) 30 days 90 days 365 days Advanced Chart Ad The Bull ReportAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. Read More to Learn How You Can Position Yourself for the Next Uranium Boom Get Rosetta Genomics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.Read More… Amazon's $150B Data Center Bet—What It Means for Uranium Investors (Ad)Amazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. Read More to Learn How You Can Position Yourself for the Next Uranium Boom Receive ROSGQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rosetta Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROSGQ Stock News Headlines10x Genomics files new EU patent suits against NanoString, VizgenJune 1, 2023 | msn.com10x Genomics launches big expansion with new Pleasanton officesMay 23, 2023 | msn.comAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. November 20, 2024 | The Bull Report (Ad)Twist Bioscience Shares Rise 16% After Launch of RNA Sequencing ToolsMay 22, 2023 | marketwatch.comOMICSEDGE FORMS STRATEGIC PARTNERSHIP WITH ALMADEN GENOMICS TO STREAMLINE DRUG DISCOVERYMay 20, 2023 | it.tmcnet.comTelo Genomics to raise $2M through private placement of unitsMay 20, 2023 | msn.comGenomics And Proteomics Reagents, Research Kits And Analytical Instruments Market Share, Analysis, Size, and Forecast 2028May 9, 2023 | marketwatch.com2023-2030 Revenue of the Single Cell Genomics MarketMay 9, 2023 | marketwatch.comSee More Headlines ROSGQ Stock Analysis - Frequently Asked Questions How do I buy shares of Rosetta Genomics? Shares of ROSGQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ROSGQ CUSIPN/A CIKN/A Webwww.rosettagenomics.com Phone972732220700Fax972-73-222-0701Employees86Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:ROSGQ) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rosetta Genomics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rosetta Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.